Growth impairment after ifosfamide-induced nephrotoxicity in children

Pediatric Blood and Cancer

Volumn 48, Issue 5, 2007, Pages 571-576

  Stöhr, Wolfgang ^a   Patzer, Ludwig ^b   Paulides, Marios ^a   Kremers, Anja ^a   Beck, Jörn Dirk ^a   Langer, Thorsten ^a   Rossi, Rainer ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b St Barbara Hospital   (Germany)

^c VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

Cancer; Children; Growth; Ifosfamide; Renal Fanconi syndrome; Tubulopathy

Indexed keywords

IFOSFAMIDE;

ADOLESCENT; ARTICLE; AUSTRIA; CHILD; CHILDHOOD CANCER; DISEASE SEVERITY; FEMALE; FOLLOW UP; GERMANY; GLOMERULUS FILTRATION RATE; GROWTH RETARDATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; QUESTIONNAIRE; SWITZERLAND; TREATMENT OUTCOME; TUBULAR DYSFUNCTION;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GLOMERULAR FILTRATION RATE; GROWTH DISORDERS; HUMANS; IFOSFAMIDE; INFANT; KIDNEY DISEASES; MALE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 33947651779     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20920     Document Type: Article

References (44)

1. Patzer L, Kentouche K, Ringelmann F, et al. Renal function following hematological stem cell transplantation in childhood. Pediatr Nephrol 2003;18:623-635.
2. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 1999;13:153-162.
3. Patzer L, Ringelmann F, Kentouche K, et al. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 2001;27:319-327.
4. Skinner R, Sharkey IM, Pearson AD, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190.
5. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003;41:190-197.
6. Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 1997;28:62-64.
7. Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with wilms tumor. J Pediatr 1990;117:331-335.
8. De Schepper J, Stevens G, Verboven M, et al. Ifosfamide-induced fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol 1991;13:39-41.
9. Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity. Lancet 1989;2:103-104.
10. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-461.
11. Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 1989;23:121-122.
12. Morland BJ, Mann JR, Milford DV, et al. Ifosfamide nephrotoxicity in children: Histopathological features in two cases. Med Pediatr Oncol 1996;27:57-61.
13. Skinner R, Pearson AD, Price L, et al. Nephrotoxicity of ifosfamide in children. Lancet 1989;2:159.
14. Suarez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 1991;9:2177-2182.
15. Van Gool S, Brock P, Wijndaele G, et al. Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol 1992;20:254-257.
16. Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996;348:578-580.
17. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996;27: 149-155.
18. Rossi R, Danzebrink S, Hillebrand D, et al. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32.
19. Smeitink J, Verreussel M, Schroder C, et al. Nephrotoxicity associated with ifosfamide. Eur J Pediatr 1988;148:164-166.
20. Rossi R, Godde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17: 551-557.
21. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, fanconi's syndrome, and rickets. J Clin Oncol 1991;9:1495-1499.
22. Rossi R, Pleyer J, Schafers P, et al. Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 1999;32;177-182.
23. Lee BS, Lee JH, Kang HG, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001;16:796-799.
24. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: AUKCCSG late effects group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000;82:1636-1645.
25. Stevens MC, Brandis M. Incidence and etiology of ifosfamide nephrotoxicity: Report of a meeting held in Rhodes, Greece, October 3, 1991, sponsored by Asia Medica, Frankfurt, Germany. Med Pediatr Oncol 1993;21:640-644.
26. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide- induced nephrotoxicity: Analysis of 120 patients. J Clin Oncol 1994;12:159-165.
27. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
28. McCune JS, Friedman DL, Schuetze S, et al. Influence of age upon ifosfamide-induced nephrotoxicity. Pediatr Blood Cancer 2004;42: 427-432.
29. Langer T, Henze G, Beck JD. Basic methods and the developing structures of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. Med Pediatr Oncol 2000;34:348-351.
30. Langer T, Stohr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 2004;42:373-379.
31. Langer T, Stohr W, Paulides M, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS). Klin Padiatr 2005;217: 176-181.
32. Brodehl J, Gellissen K, Weber HP. Postnatal development of tubular phosphate reabsorption. Clin Nephrol 1982;17:163-171.
33. Rossi R, Danzebrink S, Linnenburger K, et al. Assessment of tubular reabsorption of sodium, glucose, phosphate and amino acids based on spot urine samples. Acta Paediatr 1994;83:1282-1286.
34. Brodehl J. The Fanconi syndrome. In: Edelmann CM Jr, editor. Pediatric Kidney Disease. Boston: Little, Brown and Company; 1992. p 1841-1871.
35. Haffner D, Weinfurth A, Manz F, et al. Long-term outcome of paediatric patients with hereditary tubular disorders. Nephron 1999;83:250-260.
36. Martinez F, Deray G, Cacoub P, et al. Ifosfamide nephrotoxicity: Deleterious effect of previous cisplatin administration. Lancet 1996;348:1100-1101.
37. Giron FF, de la Vega RL, Eguinoa JE, et al. End-stage chronic renal failure secondary to cisplatin and ifosfamide combination chemotherapy. Nephron 1999;82:281-283.
38. Friedlaender MM, Haviv YS, Rosenmann E, et al. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy. Am J Nephrol 1998;18:131-133.
39. Skinner R, Parry A, Price L, et al. Ten year follow-up of renal function after ifosfamide or platinum treatment. Pediatr Blood Cancer 2005;45:554-555.
40. Challa A, Krieg RJ Jr, Thabet MA, et al. Metabolic acidosis inhibits growth hormone secretion in rats: Mechanism of growth retardation. Am J Physiol 1993;265:E547-E553.
41. Rodriguez-Soriano J, Vallo A. Renal tubular acidosis. Pediatr Nephrol 1990;4:268-275.
42. Thomas L. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; 2000.
43. Brandt I, Reinken L. [The growth rate of healthy children in the first 16 years: Bonn-Dortmund longitudinal developmental study]. Klin Padiatr 1988;200:451-456.
44. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571-590.